CSBR
NASDAQ · Life Sciences Tools & Services
Champions Oncology Inc
$6.55
+0.02 (+0.31%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 22.34M | 19.71M | 19.48M |
| Net Income | 3.45M | 2.89M | 3.05M |
| EPS | — | — | — |
| Profit Margin | 15.4% | 14.6% | 15.7% |
| Rev Growth | -7.0% | +2.4% | -6.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 36.09M | 33.95M | 38.63M |
| Total Equity | 55.15M | 59.74M | 52.97M |
| D/E Ratio | 0.65 | 0.57 | 0.73 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.06M | 6.10M | 5.64M |
| Free Cash Flow | 2.57M | 2.36M | 1.92M |